Customize
Quick Links
Specialties

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. These activites are not approved for AMA PRA Category 1 Credit™.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder Cancers PER Pulse™ Recap

PER Pulse Recap

PER Pulse™ Recap



1 of 3

Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder Cancers is a series of short content summaries and video interviews with the faculty of a live CME-certified symposium held in February 2017 in Orlando, Fla. During this online activity, expert faculty discuss immunotherapy-based standards of care and emerging strategies for a variety of solid tumors. It features commentary on:

  • Frontline therapy for squamous non-small cell lung cancer (NSCLC) by Roy Herbst, MD, PhD
  • Management of p16-positive (cyclin-dependent kinase inhibitor 2A), human papilloma virus (HPV)-positive, head and neck squamous cell carcinoma (HNSCC) by Robert Ferris, MD, PhD
  • Treatment of metastatic urothelial carcinoma that has progressed on platinum therapy by Daniel Petrylak, MD
  • Adverse event (AE) management for patients receiving immunotherapy by Ezra Cohen, MD

The first of 1 PER Pulse™ Recaps summarizing the program focuses on Dr. Herbst’s answers to questions about frontline therapy for squamous NSCLC, during which he discussed:

  • His treatment approach with a 67-year-old female current smoker with a 47-pack per year smoking history, diagnosed with stage IV NSCLC (squamous histology, no brain metastasis)
  • Treatment plans for patients with NSCLC that has metastasized to the brain
  • Key factors that should be integrated into treatment decision-making for a patient with NSCLC and an autoimmune disorder (eg, rheumatoid arthritis) when considering immunotherapy
  • The involvement of PD-L1 (programmed death-ligand) and tumor inflammation in resistance to anti–programmed cell death 1 (PD-1) therapy in patients with NSCLC
  • Use of biomarkers/molecular testing for NSCLC in everyday practice and efforts of the Blueprint PD-L1 IHC (immunohistochemistry) Assay Comparison Project to answer questions about 4 available assays
  • Investigational strategies, such as immunotherapy-containing combination approaches (eg, CTLA4 [cytotoxic T lymphocyte associated protein 4] + PD-1 or PD-L1; PD-1 + anti-VEGFR antibody [antivascular endothelial growth factor])


2 of 3
PER Pulse™ Recap

Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder Cancers is a series of short content summaries and video interviews with the faculty of a live CME-certified symposium held in February 2017 in Orlando, Fla. During this online activity, expert faculty discuss standards of care and emerging in immunotherapy. It features commentary on:

  • Frontline therapy for squamous non-small cell lung cancer by Roy Herbst, MD, PhD
  • Management of p16-positive (cyclin-dependent kinase inhibitor 2A), human papilloma virus (HPV)-positive, head and neck squamous cell carcinoma (HNSCC) by Robert Ferris, MD, PhD
  • Treatment of metastatic urothelial carcinoma that has progressed on platinum therapy by Daniel Petrylak, MD
  • Adverse event (AE) management for patients receiving immunotherapy by Ezra Cohen, MD

The second of 3 PER Pulse™ Recaps summarizing the program, focuses on Dr. Ferris’s interview, during which he discussed:

  • His treatment approach with a 51-year-old male patient with a history of smoking, status postresection for a T2N2c p16-positive, HPV-positive SCC (squamous cell carcinoma) of the base of the tongue (with extracapsular disease), who presents with a lung metastases 4 months after completion of cisplatin/radiotherapy.
  • The rationale for using anti-PD-1 (programmed cell death) therapy in HNSCC, specifically the relatively common overexpression of PD-L1 (programmed death-ligand) observed in these tumors.
  • The significant unmet needs of patients with platinum-refractory HNSCC and the importance of the introduction of checkpoint inhibitory agents in this setting
  • Anticipated changes to related practice recommendations—for example, recently presented data suggest that response rates among patients with nasopharyngeal carcinomas who receive checkpoint inhibitor therapy are similar to those of patients with other types of HNSCC
  • Ongoing trials of immunotherapies in HNSCC, including anti-PD-1 or anti-PD-L1 agents combined with a CTLA4 (cytotoxic T lymphocyte associated protein 4) inhibitor, chemotherapy, or chemoradiation—trials are being conducted in the setting of recurrence ≥ 6 months after platinum therapy, recurrence < 6 months after platinum, and as curative therapy for patients with high-risk, local-regionally advanced HNSCC

3 of 3
PER Pulse™ Recap

Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder Cancers is a series of short content summaries and video interviews with the faculty of a live CME-certified symposium held in February 2017 in Orlando, Fla. During this online activity, expert faculty discuss standards of care and emerging in immunotherapy. It features commentary on:

  • Frontline therapy for squamous non-small cell lung cancer by Roy Herbst, MD, PhD
  • Management of p16-positive, HPV-positive, head and neck squamous cell carcinoma (HNSCC) by Robert Ferris, MD, PhD
  • Treatment of metastatic urothelial carcinoma that has progressed on platinum therapy by Daniel Petrylak, MD
  • Adverse event (AE) management for patients receiving immunotherapy by Ezra Cohen, MD

This third of 3 PER Pulse™ Recaps summarizing the program focuses on Dr. Cohen’s interview, during which he discussed:

  • His treatment approach with a patient who develops pneumonitis 9 weeks after initiation of pembrolizumab for metastatic non-small cell lung cancer
  • Aspects of immune-related AE (irAE) management he has found most challenging in his own practice
  • His preferences regarding oral versus intravenous steroids to treat irAEs, and his decision-making process when d switching from one to another
  • His perspectives on using infliximab to manage irAEs that are refractory to corticosteroids
  • Key considerations when distinguishing an infection from an irAE
  • How he counsels patients about the potential for irAEs






Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
Filter By